Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Eugene D . Kwon, M.D.

Back to Research Profile

  1. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 2009 Sep 15; 183(6):3634-41. Epub 2009 Aug 26.
    View PubMed
  2. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009 Sep 3; 114(10):2149-58. Epub 2009 Jul 13.
    View PubMed
  3. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED. T-cell Co-regulatory Molecule Expression in Renal Angiomyolipoma and Pulmonary Lymphangioleiomyomatosis. Urology 2009 Jun 05. [Epub ahead of print]
    View PubMed
  4. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009 May 15; 115(10):2092-103.
    View PubMed
  5. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 2009 Mar 15; 15(6):2174-80. Epub 2009 Mar 10.
    View PubMed
  6. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer 2008 Oct 1; 113(7):1544-51.
    View PubMed
  7. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Urol 2008 Oct; 180(4 Part 1):1302.
    View PubMed
  8. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. Urology 2008 Oct; 72(4):927-32. Epub 2008 Mar 28.
    View PubMed
  9. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008 Aug 15; 14(16):5150-7. Epub 2008 Aug 11.
    View PubMed
  10. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008 Aug 1; 14(15):4800-8.
    View PubMed
  11. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008 Aug 1; 68(15):6054-8.
    View PubMed
  12. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008 Aug 1; 68(15):6054-8.
    View PubMed
  13. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008 Aug 1; 113(3):450-60.
    View PubMed
  14. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol 2008 Aug; 39(8):1176-84. Epub 2008 Jun 05.
    View PubMed
  15. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008 Jun 15; 112(12):2676-82.
    View PubMed
  16. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 2008 Jun; 179(6):2158-63.
    View PubMed
  17. Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA, Kwon ED. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 2008 May; 179(5):1954-9; discussion 1959-60. Epub 2008 Mar 20.
    View PubMed
  18. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008 Apr 1; 112(7):1471-9.
    View PubMed
  19. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, Kwon ED. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol 2008 Mar 1; 180(5):3578-84.
    View PubMed
  20. Magera JS Jr, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008 Feb; 71(2):278-82.
    View PubMed
  21. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008 Feb; 179(2):468-71; discussion 472-3.
    View PubMed
  22. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008 Feb; 179(2):468-71; discussion 472-3.
    View PubMed
  23. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007 Aug 15; 67(16):7893-900. Epub 2007 Aug 08.
    View PubMed
  24. Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer 2007 Aug 15; 110(4):783-90.
    View PubMed
  25. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007 Apr 15; 109(8):1499-505.
    View PubMed
  26. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007 Apr 1; 13(7):2075-81.
    View PubMed
  27. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2007 Apr 1; 112(7):1471-9.
    View PubMed
  28. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007 Apr 1; 13(7):2075-81.
    View PubMed
  29. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007 Mar 15; 13(6):1749-56.
    View PubMed
  30. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007 Feb; 7(1):15-30.
    View PubMed
  31. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007 Jan 15; 13(2 Pt 2):667s-670s.
    View PubMed
  32. Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007 Jan; 99(1):60-7.
    View PubMed
  33. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006 Dec; 5(3):206-11.
    View PubMed
  34. Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006 Nov; 176(5):1990-5.
    View PubMed
  35. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol 2006 Nov; 176(5):1978-82; discussion 1982-3.
    View PubMed
  36. Blocki FA, Radhakrishnan S, Van Keulen VP, Heckman KL, Ciric B, Howe CL, Rodriguez M, Kwon E, Pease LR. Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB J 2006 Nov; 20(13):E1780-9.
  37. Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology 2006 Sep; 68(3):604-8. Epub 2006 Sep 18.
    View PubMed
  38. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol 2006 Sep-Oct; 24(5):442-7.
    View PubMed
  39. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol 2006 Sep; 176(3):900-3; discussion 903-4.
    View PubMed
  40. Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 2006 Aug 15; 107(4):712-20.
    View PubMed
  41. Krambeck AE, Thompson RH, Dong HD, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006 Jul 5; 103(27):10391-6.
    View PubMed
  42. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006 Jul 1; 107(1):46-53.
    View PubMed
  43. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006 Jul 1; 107(1):37-45.
    View PubMed
  44. Parker AS, Kosari F, Lohse CM, Thompson RH, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006 Jul 1; 107(1):37-45.
    View PubMed
  45. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006 Apr 1; 66(7):3381-5.
    View PubMed
  46. Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006 Jan 15; 106(2):304-12.
    View PubMed
  47. Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol 2006 Jan; 175(1):53-6.
    View PubMed
  48. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des 2006; 12(7):807-17.
    View PubMed
  49. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: Biology, therapeutics, and challenges. J Clin Oncol 2005 Nov 10; 23(32):8262-9.
    View PubMed
  50. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol 2005 Nov; 174(5):1759-63.
    View PubMed
  51. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 2005 Jul 1; 104(1):53-60.
    View PubMed
  52. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol 2005 Jun; 173(6):1893-6.
    View PubMed
  53. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, Zincke H. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol 2005 Feb; 173(2):380-4.
    View PubMed
  54. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004 Nov 15; 173(10):6098-108.
    View PubMed
  55. Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik E, Shankey TV. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res 2004 Apr; 16(2):99-104.
    View PubMed
  56. Krejci KG, Markiewicz MA, Kwon ED. Immunotherapy for urological malignancies. J Urol 2004 Feb; 171(2 Part 1):870-6.
    View PubMed
  57. Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik EM, Shankey TV. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res 2004; 16:99-104.
    View PubMed
  58. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer 2003 Apr 1; 97(7):1663-71.
    View PubMed
  59. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer - Advances in immunotherapy. Biodrugs 2003; 17(2):131-8.
    View PubMed
  60. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 2002 Dec 15; 62(24):7135-8.
    View PubMed
  61. Moore DK, Kwon EE, Donovan JF. Continent jejunal reservoir dialysis for end-stage renal disease: is it possible? J Endourol 2002 Oct; 16(8):575-80.
    View PubMed
  62. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001 Dec 4; 98(25):14565-70.
    View PubMed
  63. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 2001 Aug 1; 61(15):5857-60.
    View PubMed
  64. Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 2001 Apr; 13(4):553-8.
    View PubMed
  65. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000 Oct; 12(5):589-96.
    View PubMed
  66. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000 May 1; 60(9):2444-8.
    View PubMed
  67. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000 May; 6(5):1755-66.
    View PubMed
  68. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999 Dec 21; 96(26):15074-9.
    View PubMed
  69. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997 Aug 15; 57(16):3325-30.
    View PubMed
  70. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997 Jul 22; 94(15):8099-103.
    View PubMed
  71. Burg MB, Kwon ED, Kultz D. Regulation of gene expression by hypertonicity. Annu Rev Physiol 1997; 59:437-55.
    View PubMed
  72. Burg MB, Kwon ED, Kultz D. Osmotic regulation of gene expression. FASEB J 1996 Dec; 10(14):1598-606.
    View PubMed
  73. Burg MB, Kwon ED, Peters EM. Glycerophosphocholine and betaine counteract the effect of urea on pyruvate kinase. Kidney Int Suppl 1996 Dec; 57:S100-4.
    View PubMed
  74. Cooper CS, Kwon ED, Donovan JF Jr. Traumatic ureteroduodenal fistula. Journal of Trauma-Injury Infection & Critical Care 1996 Sep; 41(3):553-5.
    View PubMed
  75. Kwon ED, Dooley JA, Jung KY, Andrews PM, Garcia-Perez A, Burg MB. Organic osmolyte distribution and levels in the mammalian urinary bladder in diuresis and antidiuresis. Am J Physiol 1996 Jul; 271(1 Pt 2):F230-3.
    View PubMed
  76. Kwon ED, Donovan JF, Schedl HP. Physical determinants of solute and water clearance by the perfused dog jejunum. J Surg Res 1996 Feb 15; 61(1):215-20.
    View PubMed
  77. Kwon ED, Zablocki K, Peters EM, Jung KY, Garcia-Perez A, Burg MB. Betaine and inositol reduce MDCK cell glycerophosphocholine by stimulating its degradation. Am J Physiol 1996 Jan; 270(1 Pt 1):C200-7.
    View PubMed
  78. Donovan JF Jr, Hade DK, Lavelle JP, Kwon ED. Continent small-intestine reservoir construction: a tapered intussusceptum promotes sustained continence. World J Urol 1996; 14(6):370-4.
    View PubMed
  79. Kwon ED, Zablocki K, Jung KY, Peters EM, Garcia-Perez A, Burg MB. Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl. Am J Physiol 1995 Jul; 269(1 Pt 1):C35-41.
    View PubMed
  80. Kwon ED, Jung KY, Edsall LC, Kim HY, Garcia-Perez A, Burg MB. Osmotic regulation of synthesis of glycerophosphocholine from phosphatidylcholine in MDCK cells. Am J Physiol 1995 Feb; 268(2 Pt 1):C402-12.
    View PubMed
  81. Kwon ED, Schedl HP, Donovan JF Jr. Deoxycholate effects on plasma solute clearance by gut perfusion in dog. J Surg Res 1994 Nov; 57(5):549-55.
    View PubMed
  82. Hade DK, Donovan JF Jr, Kwon ED, Stokes JB, Bertholf MB, Flanigan MJ, Schedl HP. The use of rhein to augment fluid and electrolyte secretion in the continent jejunal reservoir. Surg Forum 1994; XLV:791-4.
  83. Kwon ED, Schedl HP, Donovan JF, Carson RA, Williams RD. Transport properties of an in situ jejunal reservoir in dogs. Am J Physiol 1992 Mar; 262(3 Pt 2):F517-22.
    View PubMed
  84. Kwon ED, Loening SA, Hawtrey CE. Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate. J Urol 1991 Mar; 145(3):524-31.
    View PubMed
  85. Kwon ED, Donovan JF, Schedl HP, Williams RD. Replacement of lost renal function: Solute and coupled urea nitrogen and hydrogen ion excretion in the jejunal reservoir/urease system. Surgical Form 1991;XLII.
  86. Loening SA, Kwon ED. Percutaneous transperineal placement of radioactive gold seed for treatment of localized prostatic carcinoma. J Endourol 1989;3(2):201-8.
  87. Kwon ED, Williams RD. Magnetic resonance imaging in the evaluation of prostate cancer. World J Urol 1989; 7:17-21.


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.